v3.26.3
License and Collaboration Agreements - Schedule of AbbVie Collaboration Agreement (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues $ 9,162 $ 29,733 $ 123,574 $ 140,104
License and royalty [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues 5,244 23,605 114,175 129,119
Abb Vie Collaboration And License Agreement        
Net cost reimbursement to (from) AbbVie included in:        
Total net cost reimbursement to (from) AbbVie (7,425) (17,030) (30,360) (47,619)
Abb Vie Collaboration And License Agreement | License and royalty [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues     100,000  
Abb Vie Collaboration And License Agreement | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense        
Net cost reimbursement to (from) AbbVie included in:        
Total net cost reimbursement to (from) AbbVie 1,911 712 3,662 1,860
Abb Vie Collaboration And License Agreement | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Net cost reimbursement to (from) AbbVie included in:        
Total net cost reimbursement to (from) AbbVie $ (9,336) $ (17,742) $ (34,022) $ (49,479)